Advanced searches left 3/3

Hormone Replacement Therapy - DOAJ

Summarized by Plex Scholar
Last Updated: 11 May 2022

* If you want to update the article please login/register

KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study

We wanted to investigate a correlation of the KRAS variant with sporadic and familial breast cancer and breast tumor characteristics. Methods Genotyping was successful in 530 sporadic postmenopausal breast cancer cases, 165 familial breast cancer cases, and 270 postmenopausal control women using the flurogenic 5' nuclease assay. A postal questionnaire and pathology findings confirmed the use of hormone replacement therapy and tumor characteristics in sporadic breast cancer cases. Using the chi-square test and logistic regression methods, correlations between the KRAS genotype and breast cancer or breast tumor characteristics were investigated. BRCA carriers or non-BRCA carriers alike, there is no evidence of correlation between the KRAS variant and the risk of sporadic and familial breast cancer. The KRAS variant was statistically significantly higher in association with human epidermal growth factor receptor 2 (the human epidermal growth factor receptor 2 - positive tumors and tumors of elevated histopathologic grade).

Source link: https://doi.org/10.1186/1471-2407-12-105


Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study

Results HRT use in patients with estrogen receptor protein positive tumors was associated with an altered control of 276 genes, according to HRT. Despite lower ER values, expression profiles based on these genes divided ER-positive tumors into two molecular subclasses, one of which was associated with HRT use and had significant improvement recurrence-free survival. A comparison of external data revealed that gene expression in tumors induced by short-term estrogen exposure was negatively correlated with gene expression induced by short-term estrogen exposure, but it was positively correlated with the use of tamoxifen.

Source link: https://doi.org/10.1186/1741-7015-4-16


Modification of blood pressure in postmenopausal women: role of hormone replacement therapy

The question of what determines the best blood pressure control is still tense, according to historian and progesterone deficiency related to menopause. Both normotensive and hypertensive women have the same BP control, as shown by the results, although some preliminary results on subgroups of later postmenopausal women with oral estrogens, in particular conjugated equine estrogens, contradicted, the majority of the studies show no adverse or positive effects of estrogen or HT administration on BP control of both normotensive and hypertensive women. Both normotensive and hypertensive postmenopause women's BP control are getting more consistent and conscient in terms of identifying positive influence on BP control of both normotensive and transdermal estrogens.

Source link: https://doaj.org/article/3334dcf5c4844ef19e81a66eb3a6e592


Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis

Abstract Background The use of hormone replacement therapy has been correlated with an elevated risk of breast cancer in breast cancer. By immunometry, plasma levels of sex hormones and Sex Hormone Binding Globulin were determined in the blood. The plasma concentrations of estradiol increased with an elevated E 2 dose, as well as the use of systemic E 2-containing HRT decreased the level of Follicle Stimulating Hormone. SHBG levels in the users of oral E 2 preparations soared mainly among users. BMI measurements between HRT users and non-users were not similar. According to 100% fidelity and 88% of the HRT users's had plasma E 2 levels above the 95% CI of non-users. Users of systemic E 2 and FSH-containing HRT preparations have plasma E 2 and FSH levels similar to premenopausal women. Valid evidence on current HRT use and menopausal status among Norwegian women aged 48 to 62 years old is provided by NOWAC questionnaires, which include current HRT use and menopausal status among Norwegian women between 48 and 62 years old.

Source link: https://doi.org/10.1186/1472-6874-8-1


Silent onset of postmenopausal endometriosis in a woman with renal failure in hormone replacement therapy: a case report

Case study We present the case of a 54-year-old Italian Caucasian woman with a history of ovarian endometriosis who underwent voluntary hormone replacement therapy for seven years. Conclusion The postmenopausal endometriosis can appear in a volatile and potentially dangerous manner. It is therefore critical to properly assess the risks and benefits of administering hormone replacement therapy to patients with recent endometriosis.

Source link: https://doi.org/10.1186/1752-1947-4-248


Hormone replacement therapy increases levels of antibodies against heat shock protein 65 and certain species of oxidized low density lipoprotein

Antibodies against heat shock protein and oxidized low density lipoprotein have been isolated in atherosclerotic lesions and plasma of patients with coronary artery disease in atherosclerotic lesions and plasma, and they may play a significant role in atherosclerosis pathogenesis. With a low and high degree of copper-mediated oxidative change of 20 postmenopausal women before and 90 days after receiving orally 0. 6 mg equine conjugate estrogen plus 2. 5 mg acetate per day, the aim of this research was to determine the effects of HRT on the immune response by monitoring plasma levels of antibodies against Hsp 65 and LDL.

Source link: https://doaj.org/article/30120d845fcb4598a591c3404e92b019


Menopause and hormone replacement therapy

Elderly people are expected to grow quickly than other groups. In Asia, the fastest rise in the elderly population will occur. For several menopausal women, increased life expectancy will be followed by several health problems. The menopausal signs are the direct result of estrogen deficiency. The management of menopause-related disorders and diseases has become a critical socioeconomic and medical problem. Hormon replacement therapy can cause or prevent any of these health problems. HRT is not recommended for oral contraceptives because of synthetic estrogen. The key reasons for stopping HRT are unwanted bleeding, fear of cancer, and negative side effects. The rebrationship between HRT and the incidence of breast cancer has been a topic of discussion for a long time. Many studies showed that there was no strong correlation between HRT use and breast cancer. Until death, ThereÎore, nwny experts, and others favour the use of HRT from the first signs of climacteric abuses until death.

Source link: https://doi.org/10.13181/mji.v10i4.42


A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke

The 'Timing Hypothesis' claims that hormone replacement therapy's benefits and risks are linked to the proximity with which it is initiated following the onset of menopause. The primary aim of this report was to determine heterogeneity in the treatment effect of HRT using Chi2 and I2 tests for younger versus older initiators of HRT. Methods: Participants in initiation trials under the age of 60 years were defined as those with mean age of participants 60 years and older initiation trials were those with mean age > 60 years. HRT users are compared to nonusers in this study, resulting in thirty-one RCTs. Conclusion: HRT's younger initiation may be more beneficial in reducing mortality and cardiac events. Younger, more symptomatic women using HRT to treat vaping issues do not appear to be at a greater risk of dying or experiencing CHD events.

Source link: https://doi.org/10.1016/j.ijcha.2019.01.001


The pubertal development mode of Chinese girls with turner syndrome undergoing hormone replacement therapy

Background Information Additional information about the pubertal growth mode of girls with Turner syndrome who have undergone hormone replacement therapy may help to create a more effective HRT regimen. This report explored the pubertal growth style of girls with TS who underwent HRT, as well as the characteristics of effective sex induction therapy in girls with TS. Patients Seventy-one patients with TS and two groups of normal Chinese girls, including two groups of elderly children. Among those with TS in stages B2 and 3 were higher than those of the control group, but the uterine volume of the control group was inversely higher than that of the TS group in stages B4 and 5 compared to that of the TS group. HRT promoted normal breast growth in girls with TS; half of the girls with TS in our report reached Tanner stage B5, but the uterus later became suboptimally.

Source link: https://doi.org/10.1186/s12902-019-0403-2

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions